Drug intelligence / Profile preview

Voltaren MAX (diclofenac)

Development stage
Approved
Lead developer
HALEON
Modality
Small Molecules
Administration
Topical
01

Overview

Voltaren MAX is a high-concentration topical analgesic gel containing 2.32% diclofenac diethylamine, specifically formulated for the treatment of pain and inflammation associated with osteoarthritis and acute soft tissue injuries. Developed by Haleon, this formulation is designed to provide localized relief with a prolonged duration of action, typically allowing for twice-daily (every 12 hours) application. As a non-steroidal anti-inflammatory drug (NSAID), diclofenac works by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of pro-inflammatory prostaglandins. The gel's specialized Emulgel technology facilitates the penetration of the active ingredient through the skin into the underlying tissues and synovial fluid. This topical delivery method achieves therapeutic concentrations at the site of pain while maintaining low systemic absorption, which significantly reduces the risk of systemic side effects such as gastrointestinal irritation or cardiovascular events compared to oral NSAID therapy.

Brand names
Voltaren MAXVoltaren 12 HourVoltaren12 HourVoltaren-12 HourVoltaren ForteVoltaren Emulgel 2%
Other names
diclofenac diethylaminediclofenac diethylammonium
02

Targets

PLA2 (Phospholipase A2 group IID)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Voltaren MAX (diclofenac).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltaren MAX (diclofenac).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call